Teva Pharmaceutical Industries (TEVA) Leads The Pack In Pre-Market Activity
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Trade-Ideas LLC identified
Teva Pharmaceutical Industries
(
) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Teva Pharmaceutical Industries as such a stock due to the following factors:
- TEVA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $328.5 million.
- TEVA traded 71,313 shares today in the pre-market hours as of 8:50 AM.
- TEVA is up 2.4% today from yesterday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in TEVA with the Ticky from Trade-Ideas. See the FREE profile for TEVA NOW at Trade-Ideas
More details on TEVA:
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The stock currently has a dividend yield of 1.9%. TEVA has a PE ratio of 41.5. Currently there are 13 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 10 rate it a hold.
The average volume for Teva Pharmaceutical Industries has been 4.4 million shares per day over the past 30 days. Teva has a market cap of $52.7 billion and is part of the health care sector and drugs industry. Shares are up 7% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Teva Pharmaceutical Industries as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
Highlights from the ratings report include:
- Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Looking ahead, unless broad bear market conditions prevail, we still see more upside potential for this stock, despite the fact that it has already risen over the past year.
- TEVA PHARMACEUTICALS reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, TEVA PHARMACEUTICALS increased its bottom line by earning $3.56 versus $1.50 in the prior year. This year, the market expects an improvement in earnings ($5.14 versus $3.56).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 80.8% when compared to the same quarter one year prior, rising from $380.00 million to $687.00 million.
- The gross profit margin for TEVA PHARMACEUTICALS is rather high; currently it is at 63.45%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 13.29% is above that of the industry average.
- You can view the full Teva Pharmaceutical Industries Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null